Claims for Patent: 9,155,471

Summary for Patent: 9,155,471

Title:	Methods and systems for spatially identifying abnormal cells
Abstract:	The present invention provides compositions and methods for imaging tumor resections.
Inventor(s):	Lee W. David, Bawendi Moungi G., Ferrer Jorge
Assignee:	Lumicell, Inc'.
Application Number:	US12958058
Patent Claims:	1. An in-vivo method for spatially determining tissue heterogeneity in a subject comprising:(a) administering a composition comprising a molecular imaging probe with optical properties in the visible spectrum of 350-670 nm to the subject; and(b) obtaining an in situ image of said tissue, wherein the image allows for selective detection of one or more diseased cells within about 1 cm from the surface of the tissue and excludes deep tissue emission,wherein the molecular imaging probe has the following formula:{'sub': i', 'j', 'k', 'm', 'n, '[S1]-P-[([S2]-F)-A-([S3]-Q)-[S4]]wherein the molecular imaging probe comprises at least one of the spacers S1, S2, S3, and S4, each independently comprising a group selected from PEG2, PEG2 attached to an amino acid, aminohexanoic acid, an amino acid sequence SRK, an amino acid D, and an amino acid C; i is 0 or 1; P is a pharmacokinetic modifier comprising a polyethylene glycol (PEG) or methoxyPEG molecule; F is a Cy5 fluorochrome; A is an amino acid sequence selected from GRKL or GGRK; Q is a QSY21 dark quencher; j is 0 or 1; k is 0 or 1; m is 0 or 1; and n is 1, 2, or 4.'}2. The method of claim 1 , wherein the probe is optimally imaged between 12 and 36 hours after administration.3. The method of claim 1 , wherein the probe is optimally imaged at less than 2 hours after administration.4. The method of claim 1 , wherein the image allows for selective detection of one or more diseased cells within about 5 mm from the surface of the tissue.5. The method of claim 1 , wherein the image allows for selective detection of one or more diseased cells within about 4 mm from the surface of the tissue.6. The method of claim 1 , wherein the image allows for selective detection of one or more diseased cells within about 3 mm from the surface of the tissue.7. The method of claim 1 , wherein the image allows for selective detection of one or more diseased cells within about 2 mm from the surface of the tissue.8. The method of claim 1 , wherein the image allows for selective detection of one or more diseased cells within about 1 mm from the surface of the tissue.9. The method of claim 1 , wherein the image is obtained using an imaging device wherein the field of view of each pixel is one cell or a fraction of a cell.10. The method of claim 1 , wherein the diseased cell is a cancer cell.11. The method of claim 1 , wherein the diseased cell is a central nervous cell claim 1 , a cardiac cell claim 1 , a bone cell claim 1 , a tendon cell claim 1 , or a muscle cell.12. The method of claim 1 , wherein the subject is a mammal.13. The method of claim 12 , wherein the subject is a human.14. The method of claim 1 , wherein the composition is administered systemically.15. The method of claim 1 , wherein the composition is administered topically in-vivo.16. The method of claim 1 , wherein the imaging probe comprises one or more fluorochromes and one or more dark quenchers.17. The method of claim 1 , wherein the molecular imaging probe has the following formula: PEG-SRK(Cy5)-GGRK(QSY21)-D.18. The method of claim 17 , wherein the PEG is between 500 g/mol and 100 claim 17 ,000 g/mol.19. The method of claim 17 , wherein the PEG is about 2 claim 17 ,000 g/mol.20. The method of claim 1 , wherein the molecular imaging probe has the following formula: C(PEG)-SRK(Cy5)-GGRK(QSY21)-D.21. The method of claim 20 , wherein the PEG is between 500 g/mol and 100 claim 20 ,000 g/mol.22. The method of claim 20 , wherein the PEG is about 20 claim 20 ,000 g/mol.23. An in-vivo method for spatially determining tissue heterogeneity in a subject comprising:(a) administering a composition comprising a molecular imaging probe with optical properties in the visible spectrum of 350-670 nm to the subject; and(b) obtaining an in situ image of said tissue, wherein the image allows for selective detection of one or more diseased cells within about 1 cm from the surface of the tissue and excludes deep tissue emission,{'sub': 'n', 'wherein the molecular imaging probe has the following formula: [QSY21-Ahx-GGRK (Cy5)-PEG2-C]-PEG, wherein n=1, 2, or 4.'}24. The method of claim 23 , wherein the PEG is between 500 g/mol and 100 claim 23 ,000 g/mol.25. The method of claim 23 , wherein the PEG is about 20 claim 23 ,000 g/mol.26. The method of claim 23 , wherein the PEG is about 40 claim 23 ,000 g/mol.